You are here: Industry Insights > AMO Pharma

News List

AMO Pharma launches late-stage study of CMD candidate pharmatimes
December 24, 2020
London-headquartered AMO Pharma has announced the launch of a ‘pivotal’ phase III study of its congenital myotonic dystrophy (CDM1) candidate AMO-02 (tideglusib).
AMO Pharma Sees Positive Results in Phase II Trials biospace
March 19, 2018
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood biospace
March 16, 2018
AMO Pharmaceuticals, Inc. announced today that it has provided final data for Phase 2 proof-of-concept studies for AMO-02
AMO Pharma Enters into Collaboration Agreement with Ranedis Pharmaceuticals for Development of RND-0 americanpharmaceuticalreview
March 15, 2017
AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, today announced it has entered a collaboration agreement with Ranedis Pharmaceuticals, a privately held U.S.